IL10 secretion accelerated corneal wound healing in mice, and IL10 receptor blockade abrogated benefit, supporting a ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...

A study from 7 institutions in Hong Kong reported that tapering of low-dose atropine before the drug was discontinued had ...

In this episode of the NeuroOp Guru in collaboration with Ophthalmology Times, host Andrew G. Lee, MD, is joined by Drew Carey, MD, to discuss pretreatment features associated with vision improvement ...

A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...

MK-8748 combines direct Tie2 pathway activation with VEGF inhibition, targeting persistent vascular leakage and vessel ...

Safety findings aligned with prior batoclimab experience, with no emergent safety liabilities reported across the phase 3 ...

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...

The US Food and Drug Administration has approved the extension of dosing intervals for Regeneron’s EYLEA HD (aflibercept) up ...

Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a move that would expand its presence in complement-mediated diseases, including ...

Renee Bovelle, MD: I am thrilled and humbled to be the first physician to lead OWL. It is a deep honor and a meaningful ...